Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
GILD: second_quarter 2026 lobbying report
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Public: Jul 20, 2026, 12:20 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues pertaining to the 340B drug discount program. Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations
Public: Jul 20, 2026, 10:47 AM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues related to drug pricing Issues related to 340B program
Public: Jul 20, 2026, 10:07 AM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-
Public: Jul 18, 2026, 1:43 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Legislative services related to corporate and international tax matters.
Public: Jul 16, 2026, 2:57 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues related to triple negative breast cancer treatment. Issues related to health access.
Public: Jul 16, 2026, 2:05 PM EDTOriginal source ↗GILD: Material agreement · New financial obligation · Other company developments
Filed 8-K for an event or period dated 2026-05-14. Material agreement; New financial obligation; Other company developments.
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:26 PM EST
- USAspending
- Collection in progress72 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:27 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- Federal Register
- Collection in progress296 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:27 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable32 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST